Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI) in Irvine was down 4.6% to $9.80 with a market cap of $1 billion. The drug maker announced Friday it was withdrawing an application for the chemotherapy side effect drug Rolontis after the FDA asked for manufacturing-related information. The company said it needed more time to comply with the FDA’s request.
San Clemente-based ophthalmic medical device maker Glaukos Corp. (NYSE: GKOS) was up 4% to $72.11 with a market cap of $2.6 billion. The company said its iStent inject study was published in a leading ophthalmic journal, marking “an important milestone for Glaukos,” according to Chief Executive Thomas Burns.